Overview

Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial

Status:
Recruiting
Trial end date:
2023-05-31
Target enrollment:
Participant gender:
Summary
To determine the efficacy of NAC to prevent clinically significant anti-TB drugs induced liver injury (AT-DILI).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mahidol University
Treatments:
Acetylcysteine
N-monoacetylcystine